The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial
Abstract
Background Long-term intraocular injections of vascular endothelial growth factor (VEGF)-neutralising proteins can preserve central vision in many patients with neovascular age-related macular degeneration. We tested the safety and tolerability of a single intravitreous injection of an AAV2 vector expressing the VEGF-neutralising protein sFLT01 in patients with advanced neovascular age-related macular degeneration. Methods This was a phase 1, open-label, dose-escalating study done at four outpatient retina clinics in the USA. Patients were assigned to each cohort in order of enrolment, with the first three patients being assigned to and completing the first cohort before filling positions in the following treatment groups. Patients aged 50 years or older with neovascular age-related macular degeneration and a baseline best-corrected visual acuity score of 20/100 or less in the study eye were enrolled in four dose-ranging cohorts (cohort 1, 2 × 10 8 vector genomes (vg); cohort 2, 2 × 10 9 vg; cohort 3, 6 × 10 9 vg; and cohort 4, 2 × 10 10 vg, n=3 per cohort) and one maximum tolerated dose cohort (cohort 5, 2 × 10 10 vg, n=7) and followed up for 52 weeks. The primary objective of the study was to assess the safety and tolerability of a single intravitreous injection of AAV2-sFLT01, through the measurement of eye-related adverse events. This trial is registered with ClinicalTrials.gov, number NCT01024998. Findings 19 patients with advanced neovascular age-related macular degener…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other approaches have relied on transgenes (e.g., sFLT-1, sFLT01) which were never administered to patients to treat nAMD, and therefore the necessary therapeutic levels for efficacy were unknown.18,19”
In the citing paper
“Other approaches have relied on transgenes (e.g., sFLT-1, sFLT01) which were never administered to patients to treat nAMD, and therefore the necessary therapeutic levels for efficacy were unknown.18,19”
In the citing paper
“Prior programs have attempted intravitreal delivery with gene therapy vectors with known limited ability to cross the ILM and ocular transduction capacity (e.g., AAV2-sFLT01).16,18,21”
In the citing paper
“Independent of the route of administration (subretinal, intravitreal, or suprachoroidal), a dose-dependent inflammatory reaction has been noted in nearly all ocular gene therapies.18,28”
In the citing paper
“Higher viral doses most commonly result in an increased antibody response [8, 16, 38], but several studies present contradicting results, with either no effect of viral dose, or a higher immune response to lower doses of AAV [39–41].”
From Characterization of anti-AAV2 neutralizing antibody levels in sheep prior to and following intravitreal AAV2.7m8 injection (2024) · cites this paper as [38]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Self-citation(1985) · Archives of Ophthalmology · doi:10.1001/archopht.1985.01050120030015 · Cited by 2,540
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Gene therapy using adeno-associated virus vectors
Daya, S., & Berns, K. I. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-08 · Cited by 926
MacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62117-0 · Cited by 796
Cideciyan, A. V., Aleman, T. S., Boye, S. L., Schwartz, S. B., Kaushal, S., Roman, A. J., Pang, J.-J., Sumaroka, A., Windsor, E. A. M., Wilson, J. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807027105 · Cited by 673
Self-citationAAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
Bennett, J., Ashtari, M., Wellman, J., Marshall, K. A., Cyckowski, L. L., Chung, D. C., McCague, S., Pierce, E. A., Chen, Y., Bennicelli, J. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002865 · Cited by 395
Singer, M. A., Awh, C. C., Sadda, S., Freeman, W. R., Antoszyk, A. N., Wong, P., & Tuomi, L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.12.016 · Cited by 356
Cited by
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
“Although non-human primate and human studies using recombinant adeno-associated vectors (rAAVs) to deliver a highly potent naturally occurring VEGF inhibitor, sFLT-1, or an anti-VEGF Fab fragment suggest that sub-retinal or intravitreal delivery of gene therapy is safe, larger trials need to be conducted to determine…”
BackgroundAdeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
“238 Similarly, subretinal injection of the same vector was well-tolerated among the elderly.”
BackgroundCurrent clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
“As such, it is not surprising that the only IVI-based clinical trials to demonstrate biological activity thus far have targeted RGCs in the inner retina either to provide direct benefit to these cells (ND4-Leber hereditary optic neuropathy [LHON])(125,126) or utilize them as a depot for secretion of an antiVEGF reagen…”
BackgroundAAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
“Heier et al.166 used an AAV2 to deliver the soluble vascular endothelial growth factor (VEGF) receptor sFlt-1 (AAV2-sFLT01) at doses between 2 108 and 2 1010 vg in 19 subjects (ClinicalTrials.gov: NCT01024998).”
BackgroundMethodInfluentialDeng, Y., Qiao, L., Du, M., Qu, C., Wan, L., Li, J., & Huang, L. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2021.02.009 · Cited by 411
Metadata
- Authors
- Heier, J. S., Kherani, S., Desai, S., Dugel, P., Kaushal, S., Cheng, S. H., Delacono, C., Purvis, A., Richards, S., Le-Halpere, A., Connelly, J., Wadsworth, S. C., Varona, R., Buggage, R., Scaria, A., & Campochiaro, P. A.
- Affiliations
- Ophthalmic Consultants of Boston (US)
- Johns Hopkins University (US)
- Retinal Consultants of Arizona (US)
- University of Massachusetts Chan Medical School (US)
- Corresponding author
- Campochiaro, Peter A
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 390
- Issue
- 10089
- Pages
- 50-61
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2615193664
- Cited by
- 229
- References
- 29
- Citations by year
- 2026: 9 · 2025: 22 · 2024: 31 · 2023: 23 · 2022: 24 · 2021: 40 · 2020: 25 · 2019: 20 · 2018: 23 · 2017: 12
- FWCI
- 21.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- neovascular age-related macular degeneration, AAV2 vector, anti-VEGF therapy, safety and tolerability, visual acuity, retinal pigment epithelium, choroidal neovascularization, intraocular inflammation, dose-limiting toxicity
- MeSH terms
- Dependovirus, Aged, Aged, 80 and over, Female, Genetic Vectors, Humans, Macular Degeneration, Male, Middle Aged, Recombinant Fusion Proteins, Visual Acuity, Genetic Therapy, Parvovirinae, Choroidal Neovascularization, Angiogenesis Inhibitors, Tomography, Optical Coherence, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. https://app.cochat.ai/papers/10.1016/s0140-6736(17)30979-0
- The paper
- Heier, J. S., Kherani, S., Desai, S., Dugel, P., Kaushal, S., Cheng, S. H., Delacono, C., Purvis, A., Richards, S., Le-Halpere, A., Connelly, J., Wadsworth, S. C., Varona, R., Buggage, R., Scaria, A., & Campochiaro, P. A. (2017). Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. The Lancet. https://doi.org/10.1016/s0140-6736(17)30979-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.